myelodysplastic syndromes (MDS) | Page 14 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Are Myelodysplastic Syndromes Underdiagnosed in Poland? A Report by the Polish Adult Leukaemia Group

Author(s): 
Drozd-Sokołowska JE, Mądry K, Waszczuk-Gajda A, Żóltak T, Sikorska A, Mital A, Wajs J, Semeńczuk G, Szmigielska-Kapłon A, Szczepańska M, Wasilewska E, Szwedyk P, Hołojda J, Wątek M, Stella-Hołowiecka B, Soroka-Wojtaszko M, Homenda W, Polak M
Primary Author: 
Drozd-Sokołowska JE
Journal Title: 
Eur J Haematol
Original Publication Date: 
Oct 2016

OBJECTIVES:

Bone Marrow Diseases: 

Palliative and End-of-Life Care in Myelodysplastic Syndromes

Author(s): 
Nickolich M, El-Jawahri A, LeBlanc TW
Primary Author: 
Nickolich M
Journal Title: 
Curr Hematol Malig Rep
Original Publication Date: 
Oct 2016

A growing literature demonstrates that MDS is associated with significant impairments in overall quality of life. Given the poor prognosis for many patients with MDS, and the considerable morbidities associated with this disease, there is a critical need to address palliative and end-of-life care needs in this population. However, palliative and end-of-life care issues are under-represented in the MDS literature.

Bone Marrow Diseases: 

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

Author(s): 
Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Eidenschink Brodersen L, Loken MR, Wells DA, Subira' D, Cullen M, Te Marvelde JG, Van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K,
Primary Author: 
Westers TM
Journal Title: 
Haematologica
Original Publication Date: 
Oct 2016

Current recommendations for diagnosing

Bone Marrow Diseases: 

A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes

Author(s): 
Liu Z, Ding K, Li L, Liu H
Primary Author: 
Liu Z
Journal Title: 
Biomed Pharmacother
Original Publication Date: 
Oct 2016

Chidamide as a newly designed and synthesized histone deacetylase inhibitor induces an antitumor effect in various cancer, and it has been used in several clinical trials such as peripheral T cell lymphoma (PTCL). Here we demonstrate that Chidamide was able to increase the acetylation levels of histone H3 and decrease HDAC activity in MDS cell lines(SKM-1,MUTZ-1)and AML cell line(KG-1).

Bone Marrow Diseases: 

Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant-New Drugs on the Horizon for Acute Myeloid Leukemia

Author(s): 
Jurcic JG
Primary Author: 
Jurcic JG
Journal Title: 
JAMA Oncol
Original Publication Date: 
Oct 2016

No abstract available.

Bone Marrow Diseases: 

Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki

Author(s): 
Matsuo M, Iwanaga M, Kondo H, Soda M, Jo T, Horio K, Takasaki Y, Kawaguchi Y, Tsushima H, Imaizumi Y, Imanishi D, Taguchi J, Sawayama Y, Hata T, Miyazaki Y
Primary Author: 
Matsuo M
Journal Title: 
Cancer Sci.
Original Publication Date: 
Oct 2016

There is evidence that radiation exposure is a causative factor of

Bone Marrow Diseases: